WVE Stock Forecast: Wave Life Sciences, WVE-007 Obesity Drug, RNA Editing Pipeline, and FDA Outlook
Updated September 2026 Wave Life Sciences Inc. (NASDAQ: WVE) is attracting growing attention from U.S. biotech investors for a reason: the company is no longer defined by a single rare-disease program. Wave now has several potentially valuable clinical and preclinical assets, including: WVE-007 , an investigational obesity and cardiometabolic treatment WVE-006 , an RNA editing candidate for alpha-1 antitrypsin deficiency WVE-008 , an RNA editing program for PNPLA3-related liver disease WVE-N531 , an exon-skipping candidate for Duchenne muscular dystrophy WVE-003 , an allele-selective candidate for Huntington’s disease A broad research collaboration with GSK The biggest source of investor interest in 2026 has been WVE-007. Unlike GLP-1 medicines that primarily reduce appetite and food intake, WVE-007 is designed to change body composition by targeting fat biology while preserving muscle. That is a compel...